Seven Fleet Capital Management LP Makes New $897,000 Investment in Silence Therapeutics PLC Sponsored ADR $SLN

Seven Fleet Capital Management LP acquired a new stake in shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 147,600 shares of the company’s stock, valued at approximately $897,000. Silence Therapeutics makes up approximately 0.7% of Seven Fleet Capital Management LP’s portfolio, making the stock its 27th biggest holding.

Several other hedge funds and other institutional investors have also recently modified their holdings of SLN. EHP Funds Inc. purchased a new stake in Silence Therapeutics during the 3rd quarter worth approximately $55,000. XTX Topco Ltd acquired a new stake in shares of Silence Therapeutics during the fourth quarter worth $71,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Silence Therapeutics by 65.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock worth $83,000 after buying an additional 5,421 shares during the period. Massar Capital Management LP purchased a new stake in shares of Silence Therapeutics during the second quarter valued at $115,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Silence Therapeutics during the third quarter valued at $112,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SLN. Jefferies Financial Group upgraded Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st. Finally, William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Silence Therapeutics Price Performance

SLN stock opened at $6.93 on Friday. The company has a market capitalization of $327.37 million, a P/E ratio of -4.36 and a beta of 1.48. Silence Therapeutics PLC Sponsored ADR has a 12 month low of $4.19 and a 12 month high of $8.40. The firm’s fifty day simple moving average is $6.79 and its 200-day simple moving average is $6.10.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Friday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The business had revenue of $0.42 million for the quarter, compared to analysts’ expectations of $1.25 million. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. As a group, sell-side analysts forecast that Silence Therapeutics PLC Sponsored ADR will post -0.95 earnings per share for the current year.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.